· 3 sources · Updated · Verified
Yingjiexin Medical Raises About $30M Series B for Injection Devices
Yingjiexin Medical disclosed approximately $30 million Series B financing on November 2, 2026, to scale injection pens and delivery-device manufacturing.
Editorial team
What happened
Yingjiexin Medical disclosed approximately $30 million Series B financing on November 2, 2026, to scale injection pens and delivery-device manufacturing.
The company and market
The Shanghai medtech company's market includes injection-device platforms used to administer GLP-1, insulin and other biologic medicines.
Financing, ownership and investors
A CICC Capital-managed fund led the financing, with other reported institutional and industrial participants. The funding is allocated toward capacity, product development and international market access.
Product, technology and operating milestones
Self-administered biologics create a supply-chain opportunity for device manufacturers, but drug demand does not automatically translate into approved orders for any specific component supplier.
Why this matters for venture capital
Competitive differentiation depends on dosage reliability, manufacturing yield, regulatory clearance, contract duration and customer concentration.
What remains unverified
VCT has no public revenue, unit shipment or device-specific regulatory approval figures from the cited announcement; these should not be inferred.
Key facts
- Company
- Yingjiexin Medical
- Announcement date
- 2026-11-02
- Classification
- Startup venture financing
- Evidence
- Primary or dated specialist reporting, linked in VCT's source section
Related VCT coverage
Review the linked startup profile and canonical investment event for funding history, investor relationships and corrected event dates. The company-reported claims above are distinguished from independently verified transaction facts.
Currency conversion
The USD equivalent uses the European Central Bank reference exchange rates from October 30, 2026, the most recent published fixing before the November 2 announcement. Amounts are rounded, and company-reported qualifiers such as 'about' or 'more than' are preserved; these are not separately disclosed USD-denominated transactions.
Follow Venture Capital Tracker on Google
Add VCT as a preferred source to see more of our venture-capital reporting in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.